Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron.

Clicks: 375
ID: 1369
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #10 of 59 articles by views in journal of pharmaceutical sciences

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Literature data pertaining to the physicochemical, pharmaceutical and pharmacokinetic properties of ondansetron hydrochloride dihydrate are reviewed to arrive at a decision on whether a marketing authorization of an immediate release solid oral dosage form can be approved based on a BCS-based biowaiver. Ondansetron, a 5HT receptor antagonist, is used at doses ranging from 4mg to 24 mg in the management of nausea and vomiting associated with chemotherapy, radiotherapy and postoperative treatment. It is a weak base and thus exhibits pH dependent solubility. However, it is able to meet the criteria of 'high solubility' as well as 'high permeability' and can therefore be classified as a BCS class I drug. Further, ondansetron hydrochloride 8mg IR tablets (Zofran 8 mg) and multiples thereof (16 mg =Zofran 8mg × 2 tablets and 24 mg =Zofran 8mg × 3 tablets) meet the criteria of 'rapidly dissolving' in dissolution testing. Ondansetron hydrochloride has a wide therapeutic window and is well-tolerated after oral administration. Based on its favorable physicochemical properties, pharmacokinetic data and the minimal risks associated with an incorrect bioequivalence decision, the BCS-based biowaiver procedure can be recommended for ondansetron hydrochloride dihydrate immediate release tablets.
Reference Key
rajawat2019biowaiver Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rajawat, Gopal Singh;Belubbi, Tejashree;Nagarsenker, Mangal S;Abrahamsson, Bertil;Cristofoletti, Rodrigo;Groot, Dirk W;Langguth, Peter;Parr, Alan;Polli, James E;Mehta, Mehul;Shah, Vinod P;Tajiri, Tomokazu;Dressman, Jennifer;
Journal journal of pharmaceutical sciences
Year 2019
DOI
S0022-3549(19)30366-1
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.